As the COVID-19 pandemic arrived in 2020, there was a limited set of biological tools already developed to perform research on SARS-CoV-2. The previous outbreak of SARS-CoV-1 in 2002 until 2004 wore off by itself, and at the time some antiviral projects and vaccine development had started. However, all projects finally stopped, and very limited R&D tools such as cell lines or animal models were optimized for research on the coronavirus.
In 2020, with the apparition of the new coronavirus SARS-CoV-2 and the worldwide pandemic of COVID-19, R&D service companies and research laboratories started to use existing research models and tools adapted to SARS-CoV-2 and create new ones: in vitro assays, ex vivo assays, in vivo tests on infectable animals for the development of COVID-19 drugs, vaccines, validation of immunological, PCR or side-flow diagnostic kits, measurement of virucidal effects of materials directly on SARS-CoV-2.
Finding the right service laboratory with the set of competencies required for a COVID-19 project, however, has been proven to be difficult.
This is why Labtoo developed a tailor-made service to support Labs, Biotechs, Medtech, and Pharma companies in their SARS-CoV-2 research programs.
Labtoo can look for any type of SARS-CoV-2 experimental services, for the development of new drugs and the development of diagnostics assays. We work with a large international network of laboratories and service companies to provide the largest options for your project.
We are specialized in tailor-made projects for the pharmaceutical and biotech industry.
Select your options and start building your project.
In vitro services to validate diagnostics assays for SARS-CoV-2 in comparativee and efficacy studies.
Perform a feasibility study by looking for existing expertise available within the network of partners
Set up a study protocole, financial quotation and preparing contracts with lab partners
Implement the study plan into a schedule, collect all needed materials and reagents and execute the service